PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

PharmaLogic Holdings Corp. has appointed Etienne Montagut as its new President and Chief Executive Officer, effective June 1, 2025.

Rhea-AI Summary

PharmaLogic Holdings Corp. has appointed Etienne Montagut as its new President and Chief Executive Officer, effective June 1, 2025. Montagut, who previously served as President, brings over 25 years of senior leadership experience in the pharmaceutical industry, with previous executive roles at Lantheus, GE HealthCare, and Ipsen. He succeeds Steve Chilinski, who retired after leading the company through 13 years of growth and will transition to Executive Chairman of the Board. The leadership change positions PharmaLogic, a leading radiopharmaceutical CDMO, to continue its expansion in novel diagnostics and therapies development.

Positive

• New CEO brings 25+ years of pharmaceutical industry leadership experience
• Smooth leadership transition with former CEO remaining as Executive Chairman
• New CEO has relevant industry experience from major companies like Lantheus, GE HealthCare, and Ipsen
• Internal promotion suggests continuity in business strategy

Negative

• Loss of long-term CEO who led 13 years of growth

Argus Session date unavailable

+1.72% session move Open Argus

Details

News Market Reaction – IPSEY

The recorded move for IPSEY in the trading session of this news was +1.72%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025.

Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across global markets. Prior to joining PharmaLogic one year ago, he held executive positions at Lantheus (NASDAQ: LNTH), GE HealthCare (NASDAQ: GEHC) and Ipsen (EURONEXT: IPN).

Steve Chilinski, who has led the company through 13 years of exceptional growth, retired as Chief Executive Officer on June 1, 2025, and will assume the role of Executive Chairman of the Board.

"I'm grateful to Steve and the Board for their trust and their confidence in PharmaLogic's future," said Etienne Montagut. "The company has experienced great success, and I'm very excited about our next chapter. PharmaLogic has talent, culture, technology, and resources to lead the future of radiopharmaceuticals and improve global patient access to novel diagnostics and therapies."

About PharmaLogic Holdings Corp.

PharmaLogic is a leading global contract development and manufacturing organization (CDMO) specialized in diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a robust network of more than 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic delivers comprehensive solutions spanning development, manufacturing, and distribution of both clinical and commercial-stage radiopharmaceutical products, all in accordance with the highest quality and regulatory standards.

Our rapidly expanding diagnostics business leverages advanced technologies to enhance patient access to novel diagnostics in oncology, cardiology, and Alzheimer's disease. In the therapeutic segment, PharmaLogic is the world's only cGMP-compliant CDMO currently manufacturing and distributing a commercial radiopharmaceutical therapeutic across more than 30 countries.

PharmaLogic is dedicated to enabling global patient access to radiopharmaceuticals through strategic development partnerships with industry innovators, advancing the future of the field and supporting our partners throughout the product lifecycle. For more information, visit radiopharmacy.com and follow us on LinkedIn.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmalogic-announces-appointment-of-etienne-montagut-as-president-and-chief-executive-officer-302470235.html

SOURCE PharmaLogic Holdings Corp

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new CEO of PharmaLogic (IPSEY)?

Etienne Montagut has been appointed as the new President and CEO of PharmaLogic, effective June 1, 2025.

What is Etienne Montagut's background before becoming PharmaLogic CEO?

Montagut has over 25 years of senior leadership experience in pharmaceuticals, previously holding executive positions at Lantheus, GE HealthCare, and Ipsen. He served as President of PharmaLogic before becoming CEO.

Who did Etienne Montagut replace as CEO of PharmaLogic?

Montagut replaced Steve Chilinski, who retired as CEO after leading the company for 13 years and transitioned to Executive Chairman of the Board.

What is PharmaLogic's main business focus?

PharmaLogic is a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals.

When did the CEO change at PharmaLogic take effect?

The CEO change took effect on June 1, 2025, with Etienne Montagut assuming the role of President and CEO.